Osteoporosis Drug Names and Formulations Available in India

This guide covers the generic name and formulation of each, NPPA pricing status, and why zoledronic acid and denosumab specifically need hospital infusion or cold-chain capability rather than being self-administered like an oral tablet.

What is alendronate and how is it formulated in India?

Alendronate is an oral bisphosphonate typically dosed once weekly, available in branded and generic tablet formulations across Indian manufacturers, and is generally the first-line choice for patients who can adhere to a weekly oral regimen and tolerate the gastrointestinal precautions bisphosphonates require, such as remaining upright for a period after dosing.

What is zoledronic acid and why is it given as an infusion rather than a tablet?

Zoledronic acid is a bisphosphonate given as a once-yearly intravenous infusion rather than an oral tablet, a formulation choice that avoids the gastrointestinal absorption issues and adherence burden of a weekly tablet, at the cost of requiring monitored administration in a facility capable of intravenous infusion. This makes it a hospital or infusion-clinic-dependent drug rather than one a patient self-administers at home.

What is denosumab and how does its dosing schedule differ from bisphosphonates?

Denosumab is a subcutaneous injection given once every six months, working through a different mechanism than bisphosphonates by targeting a specific pathway in osteoclast-mediated bone resorption. It is commonly used where bisphosphonates are contraindicated, particularly in patients with significantly reduced kidney function, since bisphosphonates carry renal dosing restrictions that denosumab does not carry in the same way.

Are these osteoporosis drug names price-controlled by NPPA?

Some oral bisphosphonate formulations, including certain alendronate presentations, sit under NPPA price monitoring as scheduled formulations, while zoledronic acid infusion and denosumab, being newer biologics and specialty infusions, largely sit outside DPCO 2013 scheduling and are priced by manufacturers National Pharmaceutical Pricing Authority. This means the oral tablet is the more price-regulated end of this drug category, while the infusion and injection carry manufacturer-set pricing.

What generic osteoporosis-related drugs are available through Jan Aushadhi?

Generic calcium carbonate and vitamin D3 supplements are widely stocked through Jan Aushadhi at low cost Pradhan Mantri Bhartiya Janaushadhi Pariyojana. Bisphosphonate and denosumab availability through the scheme is more limited than for these basic adjunct supplements, meaning a hospital cannot rely on Jan Aushadhi alone for its full osteoporosis formulary.

Does raloxifene appear as an osteoporosis drug name in Indian prescribing?

Raloxifene, a selective oestrogen receptor modulator, is available in India as a further option for post-menopausal women who cannot use bisphosphonates, though it is prescribed less frequently than alendronate or denosumab and carries its own distinct side-effect profile, including an increased venous thromboembolism risk that limits its use in some patients.

What storage and administration capability does a hospital pharmacy need across these four drug names?

Alendronate needs only standard room-temperature tablet storage. Zoledronic acid needs infusion-capable staffing and monitoring on the day of administration. Denosumab needs cold-chain storage at 2-8°C and injection administration capability. Raloxifene, an oral tablet, needs only standard storage like alendronate. A hospital pharmacy stocking the full range needs to plan for this spread of requirements rather than treating "osteoporosis drugs" as one uniform stocking category.

Why does brand and formulation consistency matter once a patient starts one of these drugs?

Once a patient is stabilised on a specific formulation and dosing schedule, particularly denosumab given its documented rebound risk on discontinuation or significant delay, switching formulation or missing a scheduled dose carries real clinical consequences beyond simple inconvenience. A hospital pharmacy's role is less about drug selection, which sits with the prescribing physician, and more about reliably delivering whichever drug and schedule has already been chosen.

Are there newer osteoporosis drug names entering Indian prescribing beyond these four?

Teriparatide, a bone-forming (anabolic) agent given as a daily subcutaneous injection, is used for severe osteoporosis where a bisphosphonate or denosumab has not been sufficient. Its higher cost and daily injection requirement limit it to a smaller patient segment than the four drugs above.

Romosozumab, a newer dual-acting agent, has more limited availability in India currently compared with established markets. A hospital pharmacy considering either drug should confirm current CDSCO approval and local distributor availability before committing formulary space to them.

How should a hospital pharmacy decide which of these osteoporosis drug names to keep in standard stock versus order on request?

Alendronate and generic calcium/vitamin D3, given their oral tablet form, low cost and high patient volume, are reasonable standard-stock items for most orthopaedic or geriatric pharmacies. Zoledronic acid and denosumab, given their infusion or cold-chain requirements and lower per-patient frequency, are often better handled through a scheduled-order model tied to a specific appointment rather than continuous walk-in stock.

This distinction matters for capital efficiency: a hospital does not need continuous zoledronic acid or denosumab inventory sitting unused between scheduled patients, but it does need a reliable, short-lead-time ordering relationship with its supplier so a scheduled dose is never delayed by a stock gap discovered too late.

How does reliable stocking of these specific drug names support post-fracture care?

A post-fracture patient started on one of these drugs at discharge needs the pharmacy to have it in stock. For zoledronic acid and denosumab specifically, the infusion or injection capability to administer it that same visit matters too.

A frail elderly patient asked to return separately for therapy initiation frequently does not come back, which is exactly why same-visit availability of the right drug name and formulation matters more here than in most other prescribing categories. Managed hospital pharmacy services and pharmacy inventory management for expiry and dead stock cover how in-house stocking and administration capability support this kind of at-discharge therapy initiation.

Do generic versions of zoledronic acid and denosumab exist in India?

Generic zoledronic acid infusion is available from multiple Indian manufacturers at meaningfully lower cost than the original branded product, making the yearly infusion more accessible than its originator pricing alone would suggest. Denosumab remains more limited to originator and a smaller number of licensed biosimilar-style versions, reflecting its more recent introduction and biologic manufacturing complexity compared with a small-molecule bisphosphonate infusion.

A hospital pharmacy comparing costs across suppliers for either drug should confirm CDSCO approval status and verify the specific manufacturer's regulatory standing, rather than assuming any lower-priced option is automatically an approved equivalent.

Sources

1. 1National Pharmaceutical Pricing Authority — drug price control and margin regulation
2. 2Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
3. 3Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
4. 4Denosumab discontinuation and rebound-associated vertebral fractures — PubMed

This article is for informational purposes and is not a substitute for professional medical advice.